Angina, Stable, Angina, Unstable, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), ST-segment Elevation Myocardial Infarction (STEMI), Vascular Diseases
Conditions
Keywords
Proteomics, Metabolomics, Atherosclerosis, Angioplasty, Vascular surgery
Brief summary
The purpose of the study is to identify proteins, metabolites and signal pathways related directly to symptomatic atherosclerosis and to disease progression. In the study, we use residual material from angioplasty catheter balloons and from vascular surgery plus blood samples. It is the hypothesis that material left on the catheter balloons used for angioplasty can be used for proteomics and metabolomics evaluation that will identify inflammation-associated proteins and signaling pathways directly in the diseased vessel. The tissue samples will be collected after the procedure and blood samples will be collected at the procedure plus after 6-12 months. The tissue and blood samples will be analyzed using mass spectrometry methods and a standard panel of biomarkers will also be analyzed using standardized methods. The analyses will include study of inflammation-associated peptides observed in autoinflammation as well as thrombogenic signaling pathways and local expression of biomarkers. The analyses of proteins, metabolites and/or biomarkers will be compared between cases (stable angina, unstable angina/non-STEMI, STEMI and vascular surgery) and controls (procedures not related to coronary artery diseases) to identify molecular processes related directly to symptomatic atherosclerosis and will be associated with disease progression using data from medical journals and National Health registries. The study will recruit 225 patients from Rigshospitalet University Hospital, Copenhagen, and Herlev-Gentofte Hospital.
Interventions
None listed
Sponsors
University of Copenhagen
Herlev and Gentofte Hospital
Rigshospitalet, Denmark
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Symptomatic atherosclerotic disease * 18 years or older * Angioplasty or vascular surgery
Exclusion criteria
\- Not willing or unable to give informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Protein composition in tissue | Baseline | Difference in protein composition in tissue (residual material from angioplasty balloons) and blood samples compaired between study groups. |
| Metabolomic composition | Baseline | Difference in metabolite composition in tissue (residual material from angioplasty balloons) and blood samples compaired between study groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biomarker composition | Baseline | Differences in biomarker composition between groups |
| Disease progression in relation to protein, metabolite and biomarker compostion | With 12 months | Changes in disease progression in relation to the protein, metabolite and biomarker composition |
| Protein composition | Within 12 months | Difference in protein composition in blood samples |
| Metabolomic composition | Within 12 months | Difference in metabolite composition in blood samples |
Countries
Denmark
Contacts
Primary ContactGorm M Hansen, MD, PhD
Backup ContactHenning Bundgaard, PhD, DMSci
Outcome results
None listed